Welcome to our dedicated page for Balchem SEC filings (Ticker: BCPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Balchem Corporation (NASDAQ: BCPC) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its operations as a global specialty ingredient manufacturer. This SEC filings page aggregates those disclosures, including current reports on Form 8-K and, via EDGAR, the company’s annual reports on Form 10-K, quarterly reports on Form 10-Q and other required filings.
Recent Form 8-K filings show how Balchem uses current reports to furnish quarterly financial results. For example, the company has filed 8-Ks under Item 2.02, “Results of Operations and Financial Condition,” to attach press releases reporting net sales, segment earnings, adjusted EBITDA and free cash flow for its Human Nutrition & Health, Animal Nutrition & Health and Specialty Products segments. Another Form 8-K details the results of Balchem’s annual meeting of shareholders, including director elections, auditor ratification and advisory votes on executive compensation.
Through this page, users can access Balchem’s periodic reports, which typically include segment information, risk disclosures, accounting policies and other data relevant to its specialty ingredients, animal nutrition and specialty chemical activities. Filings related to governance matters, such as shareholder voting outcomes, are also available.
Stock Titan enhances these filings with AI-powered summaries that explain complex sections in plain language, highlight key segment trends and clarify items such as non-GAAP measures referenced in Balchem’s earnings releases. Real-time updates from EDGAR help users see new 10-K, 10-Q and 8-K filings as they are posted, while Form 4 and other ownership-related filings can be reviewed to monitor insider transactions. This combination of official documents and AI-assisted analysis allows investors and researchers to study Balchem’s regulatory history, financial reporting and governance practices in a structured and accessible way.
Balchem Corporation delivered higher first-quarter 2026 results, with net sales rising to $270.7 million from $250.5 million and net earnings increasing to $40.3 million from $37.1 million. Diluted EPS grew to $1.25 from $1.13.
Gross margin expanded to 37.3% of sales from 35.2%, supported by growth across Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products, partly offset by higher raw material and compensation costs. Operating margin remained strong at about 20.5%.
Operating cash flow was $40.1 million, funding $6.3 million of capital and intangible investments, $30.8 million of dividends, and $15.7 million of share repurchases. Total assets were $1.69 billion, with a $169 million revolving loan balance and stockholders’ equity of $1.29 billion.
Comprehensive income was reduced by a $9.8 million other comprehensive loss, mainly from foreign currency translation. Management notes ongoing monitoring of geopolitical tensions and evolving U.S. tariff policies but does not currently expect a material impact on future results or cash flows based on available information.
Balchem Corporation reported strong results for the first quarter of 2026, showing growth across all segments. Net sales were $270.7 million, up 8.1% from a year earlier, with GAAP net earnings of $40.3 million, up 8.7%. Adjusted EBITDA reached $74.3 million, an increase of 12.1%.
GAAP diluted earnings per share were $1.25 versus $1.13 in the prior-year quarter, while adjusted diluted EPS was $1.33 versus $1.22. Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products all delivered higher sales and earnings from operations, with Specialty Products achieving record earnings.
Cash flows from operations were $40.1 million and free cash flow was $33.8 million. Balchem returned capital through a $30.8 million dividend and $15.7 million of share repurchases and ended the quarter with $72.9 million in cash, $169.0 million of revolving debt and net debt of $96.1 million.
Vanguard Capital Management reported beneficial ownership of 1,680,971 shares of Balchem Corp common stock, representing 5.24% of the class as of 03/31/2026. The filing shows sole voting power over 248,883 shares and sole dispositive power over 1,680,971 shares. The Schedule 13G filing is signed on 04/29/2026 by Ashley Grim as Head of Global Fund Administration and states the holdings include securities held for Vanguard funds and managed accounts.
Balchem Corp ownership disclosure: Vanguard Portfolio Management reports beneficial ownership of 2,221,969 shares of Common Stock, representing 6.93% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over 2,221,969 shares and sole voting power for 28,552 shares. The disclosure attributes holdings to Vanguard Portfolio Management LLC and affiliates and is signed by a Vanguard officer on 04/28/2026.
Balchem Corporation will hold its 2026 Annual Meeting of Shareholders virtually on June 18, 2026, at 8:30 a.m. EDT. Shareholders of record as of April 21, 2026 can vote online, by phone, or by mail.
Investors are being asked to elect two Class 3 directors to serve until 2029, ratify RSM US LLP as independent auditor for the 2026 fiscal year, and approve on an advisory basis the compensation of named executive officers. The Board unanimously recommends voting FOR all three proposals.
The proxy highlights a governance framework with six independent directors out of seven, a Lead Director, board retirement at age 70, regular self-assessments, and active risk oversight covering cybersecurity, artificial intelligence, and sustainability. Executive pay emphasizes performance, using an Incentive Compensation Plan based on Adjusted EBITDA, revenue, free cash flow, and an ESG modifier. For 2025, Adjusted EBITDA was $274.9 million, revenue was $1,037.2 million, free cash flow was $173.6 million, and ICP payouts were 176.8% of target, reflecting these results.
Balchem Corp’s Chief Accounting Officer Erin Leigh Gilson filed an initial ownership report listing her existing equity position in the company. The filing shows employee stock options covering multiple blocks of common stock with exercise prices from $74.57 to $143.43 and expirations between 2028 and 2034.
Gilson also holds 2,440 shares of common stock directly and 46 shares indirectly through a 401(k) plan as of the reported date. Footnotes describe restricted stock awards of 1,330 shares that vest after three years and 1,110 shares that vest over three years with staged annual vesting.
The Vanguard Group reports it beneficially owns 0 shares (0%) of Balchem Corp common stock. The filing amends prior Schedule 13G filings to reflect an internal realignment effective January 12, 2026, under which certain Vanguard subsidiaries will report holdings separately.
This amendment states Vanguard holds no voting or dispositive power over Balchem common stock and that no single outside person is known to hold more than 5% of the class on Vanguard's behalf. The filing is signed by Ashley Grim on 03/26/2026.
Balchem Corporation filed its annual report describing a diversified specialty ingredients business across Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The company serves food, beverage, pharmaceutical, animal health, plant nutrition and industrial markets worldwide.
Backlog was $53,365 thousand at December 31, 2025, modestly above $50,415 thousand a year earlier, with all orders expected to ship in 2026. Balchem invested $43,193 thousand in capital projects and $18,510 thousand in R&D during 2025 to expand capacity, improve efficiency and develop new products.
The company highlights regulatory and environmental exposure around ethylene oxide and propylene oxide, global supply chain and geopolitical risks, cybersecurity threats, labor availability, and raw material inflation. As of year-end 2025 Balchem employed about 1,352 full-time staff worldwide and continued share repurchases, buying back 684,927 shares during 2025.
Balchem Corporation reported strong fourth quarter and full year 2025 results, with broad-based growth across all segments. In Q4 2025, net sales rose 9.8% to $263.6 million, GAAP net earnings increased 16.8% to $39.2 million, and adjusted EBITDA reached $67.9 million. GAAP diluted EPS was $1.21 versus $1.03 a year earlier, while adjusted diluted EPS improved to $1.31 from $1.13. Free cash flow for the quarter was $51.2 million.
For full year 2025, Balchem delivered record net sales of $1.037 billion, up 8.8%, and record GAAP net earnings of $154.8 million, up 20.5%. GAAP diluted EPS increased to $4.75 from $3.93, and adjusted diluted EPS rose to $5.15 from $4.37. Record adjusted EBITDA was $274.9 million, and record free cash flow was $173.6 million, supported by net cash from operating activities of $216.6 million. All three segments — Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products — grew sales and earnings from operations year over year. The company ended 2025 with $74.6 million of cash, revolving loan borrowings of $164.0 million, net debt of $89.4 million, and a net leverage ratio of 0.3x, after significant share repurchases and a double-digit dividend increase.
Balchem Corporation appointed Erin L. Gilson as Vice President and Chief Accounting Officer, effective April 1, 2026. She succeeds William A. Backus, whose retirement from the same role on March 31, 2026 had been previously announced.
Gilson has been with Balchem since February 2016 and currently serves as Senior Director of Accounting and Financial Reporting. The company states there are no material changes to her compensatory arrangement in connection with this election.